Alector Inc
NASDAQ:ALEC
Intrinsic Value
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. [ Read More ]
The intrinsic value of one ALEC stock under the Base Case scenario is 11.31 USD. Compared to the current market price of 5.16 USD, Alector Inc is Undervalued by 54%.
Valuation Backtest
Alector Inc
Run backtest to discover the historical profit from buying and selling ALEC stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Alector Inc
Current Assets | 565.8m |
Cash & Short-Term Investments | 548.9m |
Other Current Assets | 16.9m |
Non-Current Assets | 56m |
PP&E | 47.1m |
Other Non-Current Assets | 9m |
Current Liabilities | 177.9m |
Accounts Payable | 3.8m |
Accrued Liabilities | 44.1m |
Other Current Liabilities | 130.1m |
Non-Current Liabilities | 309.7m |
Other Non-Current Liabilities | 309.7m |
Earnings Waterfall
Alector Inc
Revenue
|
97.1m
USD
|
Operating Expenses
|
-248.8m
USD
|
Operating Income
|
-151.7m
USD
|
Other Expenses
|
21.3m
USD
|
Net Income
|
-130.4m
USD
|
Free Cash Flow Analysis
Alector Inc
What is Free Cash Flow?
ALEC Profitability Score
Profitability Due Diligence
Alector Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
Score
Alector Inc's profitability score is 26/100. The higher the profitability score, the more profitable the company is.
ALEC Solvency Score
Solvency Due Diligence
Alector Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Score
Alector Inc's solvency score is 52/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALEC Price Targets Summary
Alector Inc
According to Wall Street analysts, the average 1-year price target for ALEC is 14.79 USD with a low forecast of 4.04 USD and a high forecast of 43.05 USD.
Ownership
ALEC Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ALEC Price
Alector Inc
Average Annual Return | -12.42% |
Standard Deviation of Annual Returns | 39.34% |
Max Drawdown | -90% |
Market Capitalization | 494.1m USD |
Shares Outstanding | 95 750 000 |
Percentage of Shares Shorted | 8.61% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Alector, Inc. operates as a clinical-stage biopharmaceutical company, which engages in pioneering of immuno-neurology. The company is headquartered in South San Francisco, California and currently employs 208 full-time employees. The company went IPO on 2019-02-07. The firm is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegeneration. The firm is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. The firm has advanced four product candidates, AL001, AL002, AL003, and AL101, into clinical development. Its first product candidate, AL001, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients. Its AL002 targets triggering receptor expressed on myeloid cells 2 (TREM2) to increase the functionality of TREM2 signaling and enhance microglia cell activation.
Contact
IPO
Employees
Officers
The intrinsic value of one ALEC stock under the Base Case scenario is 11.31 USD.
Compared to the current market price of 5.16 USD, Alector Inc is Undervalued by 54%.